Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B‐cell lymphomas

• Published in: British journal of haematology 2007-01, Vol.136 (1), p.38-47
• Main Authors: Muris, J. J. F., Ylstra, B., Cillessen, S. A. G. M., Ossenkoppele, G. J., Kluin‐Nelemans, J. C., Eijk, P. P., Nota, B., Tijssen, M., De Boer, W. P. H., Van De Wiel, M., Van Den Ijssel, P. R. L. A., Jansen, P., De Bruin, P. C., Van Krieken, J. H. J. M., Meijer, G. A., Meijer, C. J. L. M., Oudejans, J. J.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; apoptosis; Apoptosis - genetics; Biological and medical sciences; Cluster Analysis; Female; gene expression; Gene Expression Profiling; Granzymes - analysis; Hematologic and hematopoietic diseases; Humans; Immunohistochemistry - methods; Lymphoma, B-Cell - genetics; Lymphoma, B-Cell - mortality; Lymphoma, B-Cell - pathology; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - pathology; lymphomas; Male; Medical sciences; Middle Aged; new drugs for lymphoma; Oligonucleotide Array Sequence Analysis; Prognosis; Survival Analysis
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/j.1365-2141.2006.06375.x

Summary Intrinsic resistance of lymphoma cells to apoptosis is a probable mechanism causing chemotherapy resistance and eventual fatal outcome in patients with diffuse large B cell lymphomas (DLBCL). We investigated whether microarray expression profiling of apoptosis related genes predicts clinical outcome in 46 patients with primary nodal DLBCL. Unsupervised cluster analysis using genes involved in apoptosis (n = 246) resulted in three separate DLBCL groups partly overlapping with germinal centre B‐lymphocytes versus activated B‐cells like phenotype. One group with poor clinical outcome was characterised by high expression levels of pro‐and anti‐apoptotic genes involved in the intrinsic apoptosis pathway. A second group, also with poor clinical outcome, was characterised by high levels of apoptosis inducing cytotoxic effector genes, possibly reflecting a cellular cytotoxic immune response. The third group showing a favourable outcome was characterised by low expression levels of genes characteristic for both other groups. Our results suggest that chemotherapy refractory DLBCL are characterised either by an intense cellular cytotoxic immune response or by constitutive activation of the intrinsic mediated apoptosis pathway with concomitant downstream inhibition of this apoptosis pathway. Consequently, strategies neutralising the function of apoptosis‐inhibiting proteins might be effective as alternative treatment modality in part of chemotherapy refractory DLBCL.